Ashington Innovation Plc
LLSE:ASHI0.75
GBX
0.00
(0.00%)
ISIN
GB00BNM4K334
Return %
Stock
S&P 500
1Y
-33.33
14.20
3Y
-82.76
81.12
5Y
- -
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Jason Smart
- Full Time Employees
- 5
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- 27/28 Eastcastle Street London LO United Kingdom W1W 8DH
- IPO Date
- Jun 6, 2023
- Website
- ashingtoninnovationplc.com
- Similar Companies
- Business
- Ashington Innovation PLC Ashington Innovation PLC (LSE:ASHI.L) is a special purpose acquisition company (SPAC) listed on the London Stock Exchange that raises capital through its initial public offering to acquire and operate businesses primarily in the technology sector; it targets financial services technology (fintech) and deep technology (deep tech) companies possessing proprietary technologies and applicable intellectual property, with a focus on creating trading businesses rather than investment holdings through capital appreciation for shareholders. Incorporated in England and Wales in 2020 and headquartered at 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom, the company conducts due diligence on acquisition opportunities without geographic limitations, potentially pursuing single significant targets or complementary businesses to form larger entities, and leverages its directors' networks in capital markets, corporate finance, and law to identify scale-up prospects amid market turbulence, geopolitical uncertainty, and funding constraints. It offers no current products or services of its own, generating no revenue and maintaining minimal operations with approximately five employees, while its business model depends entirely on successful mergers. Recent developments include the termination in January 2024 of a proposed reverse takeover of Cell Therapy Limited and a conditional acquisition of Calon Cardio-Technology Limited due to uncertain funding availability under prevailing market conditions, alongside amendments to its articles of association approved via special resolution at a general meeting in July 2025, share issuances and fundraises in 2024, and ongoing evaluations of accretive technology sector opportunities as of late 2025.